Literature DB >> 25629890

Achievement of Therapeutic Vancomycin Trough Serum Concentrations with Empiric Dosing in Neonatal Intensive Care Unit Patients.

Theresa Ringenberg1, Christine Robinson, Rachel Meyers, Lisa Degnan, Pooja Shah, Anita Siu, Marc Sturgill.   

Abstract

BACKGROUND: The recommended goal serum trough concentration for vancomycin has increased to 10 to 20 mcg/mL, with a higher range of 15 to 20 mcg/mL for serious infections due to methicillin-resistant Staphylococcus aureus in children and adults. Although neonatal references have also recommended these higher target concentrations, dosing recommendations remained unchanged. The objective of this study was to assess the percentage of neonates and young infants achieving a serum trough concentration between 10 and 20 mcg/mL with empiric vancomycin dosing based on Neofax® in a neonatal intensive care unit (NICU) population.
METHODS: A multi-institutional retrospective chart review was conducted to identify NICU patients who received a minimum of three doses of intravenous vancomycin and had at least one appropriately drawn trough. Additional outcomes included the duration of vancomycin therapy, number of dose adjustments required to attain goal trough concentrations, time to goal trough, and incidence of nephrotoxicity and ototoxicity.
RESULTS: Of the 171 vancomycin serum trough concentrations included in the primary outcome, only 25.1% achieved a goal trough of 10 to 20 mcg/mL with empiric dosing. Only 44.6% of patients achieved the goal trough of 10 to 20 mcg/mL at any time during their vancomycin therapy. The average gestational age was 28.2 ± 4.1 weeks, average postnatal age at start of vancomycin was 34.1 ± 34.6 days, and average weight of the patients at start of vancomycin was 1602 ± 1014.5 g. The average and median total daily dose in those patients who achieved an initial vancomycin trough of 10-20 mcg/mL were 32.4 mg/kg/day and 30 mg/kg/day, respectively.
CONCLUSION: Dosing of vancomycin based on Neofax® in NICU patients is insufficient in yielding serum trough concentrations of 10 to 20 mcg/mL. Further studies are needed to evaluate the optimal dosing regimen to achieve higher trough concentrations in this patient population.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25629890     DOI: 10.1097/INF.0000000000000664

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  13 in total

1.  Vancomycin dosing and therapeutic drug monitoring practices: guidelines versus real-life.

Authors:  Tatjana Van Der Heggen; Franky M Buyle; Barbara Claus; Annemie Somers; Petra Schelstraete; Peter De Paepe; Sophie Vanhaesebrouck; Pieter A J G De Cock
Journal:  Int J Clin Pharm       Date:  2021-04-28

2.  Vancomycin Use in a Paediatric Intensive Care Unit of a Tertiary Care Hospital.

Authors:  Kannan Sridharan; Amal Al-Daylami; Reema Ajjawi; Husain Am Al Ajooz
Journal:  Paediatr Drugs       Date:  2019-08       Impact factor: 3.022

3.  Implementation of a Vancomycin Dose-Optimization Protocol in Neonates: Impact on Vancomycin Exposure, Biological Parameters, and Clinical Outcomes.

Authors:  Laura Gomez; Diane Boegler; Chloé Epiard; Layli Alin; Julie Arata-Bardet; Yvan Caspar; Thierry Debillon; Françoise Stanke-Labesque; Elodie Gautier-Veyret
Journal:  Antimicrob Agents Chemother       Date:  2022-04-25       Impact factor: 5.938

4.  Implementation of a Pharmacist-Driven Vancomycin and Aminoglycoside Dosing Service in a Pediatric Hospital.

Authors:  Sara W Hovey; Jessica L Jacobson; Kristen M Welsh; Betty N Vu
Journal:  J Pediatr Pharmacol Ther       Date:  2022-05-09

5.  Population pharmacokinetics of vancomycin and AUC-guided dosing in Chinese neonates and young infants.

Authors:  Yewei Chen; Dan Wu; Min Dong; Yiqing Zhu; Jinmiao Lu; Xiaoxia Li; Chao Chen; Zhiping Li
Journal:  Eur J Clin Pharmacol       Date:  2018-03-30       Impact factor: 2.953

6.  An Academic Multihealth System PGY2 Pediatric Pharmacy Residency Program.

Authors:  Theresa Klosterman; Rachel Meyers; Anita Siu; Pooja Shah; Katelin Kimler; Marc Sturgill; Christine Robinson
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Nov-Dec

7.  Assessment of Empiric Vancomycin Regimen in the Neonatal Intensive Care Unit.

Authors:  Ruthdol Ywaya; Brandi Newby
Journal:  Can J Hosp Pharm       Date:  2018-06-30

8.  Predictive Performance of a Vancomycin Population Pharmacokinetic Model in Neonates.

Authors:  Chris Stockmann; Adam L Hersh; Jessica K Roberts; Jiraganya Bhongsatiern; Ernest K Korgenski; Michael G Spigarelli; Catherine M T Sherwin; Adam Frymoyer
Journal:  Infect Dis Ther       Date:  2015-05-22

9.  Model-Informed Precision Dosing of Vancomycin in Hospitalized Children: Implementation and Adoption at an Academic Children's Hospital.

Authors:  Adam Frymoyer; Hayden T Schwenk; Yvonne Zorn; Laura Bio; Jeffrey D Moss; Bhavin Chasmawala; Joshua Faulkenberry; Srijib Goswami; Ron J Keizer; Shabnam Ghaskari
Journal:  Front Pharmacol       Date:  2020-04-29       Impact factor: 5.810

10.  Vancomycin is commonly under-dosed in critically ill children and neonates.

Authors:  Natasha Sosnin; Nigel Curtis; Noel Cranswick; Roberto Chiletti; Amanda Gwee
Journal:  Br J Clin Pharmacol       Date:  2019-08-30       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.